| abstract |
The invention relates to the application of Ekmanella muciniphila in the preparation of β-chenodeoxycholic acid inhibitor. Studies have found that Ekmanella mucinophila can reduce the level of serum bile acid β-chenodeoxycholic acid, increase insulin secretion capacity, increase the expression level of FGF15/19, promote glycogen synthesis and reduce gluconeogenesis, and improve glucose. Tolerance, and Ekmania muciniphila is a normal microorganism in the healthy gut, which can be ingested for a long time with high safety. Therefore, Ekmania muciniphila can be used as a chenodeoxycholic acid inhibitor, and a drug or health care product for improving glucose tolerance with high safety can be developed. |